Capsugel today announced that it has completed its acquisitions of Xcelience and Powdersize. Xcelience and Powdersize are now part of Capsugel’s Dosage Form Solutions business unit, which partners with pharmaceutical and health and nutrition customers around the world to advance products through an integrated approach to the design, development and manufacture of high-quality, innovative dosage forms.
The acquisitions, announced on December 14, 2015, provide Capsugel with specialized clinical trial manufacturing and supply capabilities for a broad range of solid dosage forms; development and manufacturing for specialized products such as highly potent and controlled substance compounds; and micronization capabilities that augment the company’s existing formulation design services and premier bioavailability enhancement technology platform. When combined with Capsugel’s wide array of industry-leading hard capsule technologies, the expanded capabilities of Capsugel Dosage Form Solutions make the company better positioned than ever to partner with customers to deliver innovative, patient-centric dosage forms and solutions.
Source: Capsugel
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.
